MedTrace Logo

Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis

NCT07140211 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9200

Last updated 2026-02-17

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the risk-benefit of a short-term treatment with a low-dose low-molecular-weight heparin (LMWH), in the postpartum period (after delivery). The main questions it aims to answer are:

* compared to no treatment, does short-term postpartum LMWH modify the risk of venous thromboembolism within 90 days of delivery?
* compared to no treatment, does short-term postpartum LMWH modify the risks of bleeding and wound complications? Participants will take low-dose LMWH for 7-10 days or no treatment, and will be followed for 90 days post-delivery.

Conditions

  • Venous Thromboembolism (VTE)
  • Postpartum

Interventions

DRUG

Low-dose low-molecular-weight heparin

Low-molecular-weight heparin given for 7-10 days after delivery: * enoxaparin 4000-6000IU o.d. * nadroparin 3800-5700IU o.d. * dalteparin 5000-7500IU o.d. * tinzaparin 4500-7000IU o.d.

Sponsors & Collaborators

  • Marc Blondon

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2030-08-31
Completion
2030-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07140211 on ClinicalTrials.gov